Active Ingredients: Isotretinoin
Partial improvement was observed in 6 patients from group I and 4 patients from group II.
Multicentre, randomized and controlled studies were carried out by Akman et al. Sixty-six patients qualified for the study were divided into 3 groups: patients from group I were given isotretinoin at the dose of 0.
After the treatment, the patients were observed for 12 months. Twenty-two patients from group I 19 females, 3 males, mean age: 22.
When the obtained results were analyzed according to the acne severity: moderate acne — 31 individuals, severe acne — 29, there were no statistically significant differences in the group of patients with moderate acne.
Over the last 15 years, apart from papers on intermittent isotretinoin therapy, there have been papers on studies on patients given low doses of isotretinoin.
In, Mandekou-Lefaki et al.
The study group consisted of 64 patients 35 females, 29 males divided into 2 groups. Thirty two subjects from group I received isotretinoin at the dose of 0.
In, Amichai et al. The patients were divided into 2 groups according to age: group I — patients aged between 12 and 20 years, and group II — patients aged from 21 to 35 years.
Twenty two patients out of 638 stopped the treatment. Improvement in skin lesions was observed, in group I in 94.
Within a 4-year observation period, recurrence was found in 3. A similar therapeutic regimen was used by Sardana et al.
Prospective studies were carried out on 320 patients diagnosed with moderately severe acne. The study was followed by a 6-month observation period.
The study was completed by 305 patients. The average cumulative dose taken by patients was 38. Within a 6-month observation period, recurrences occurred in 50 16.